Umoja Biopharma

Umoja Biopharma is a Seattle-based clinical-stage immuno-oncology company developing in vivo CAR T cell therapies for cancer. Its VivoVec lentiviral platform generates CAR T cells directly in a patient's body, removing the ex vivo manufacturing step of traditional cell therapy, and the company operates its own manufacturing facility in Louisville, Colorado. Its pipeline includes UB-VV111 (CD19), UB-VV400 (the industry's first known CD22-directed in vivo CAR T candidate, FDA IND clearance July 2026), and UB-VV500. Umoja is backed by investors including DCVC (DCVC Bio) and SoftBank Vision Fund 2. The company publishes no public developer API, OpenAPI, or developer portal; this profile captures the company identity and the security posture of its public web surface.

Umoja Biopharma is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Immunotherapy, Cart, and Cell Therapy.

Umoja Biopharma’s developer surface includes engineering blog and 9 more developer resources.

🌐 Visit website 📡 Source on GitHub
6.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyBiotechnologyImmunotherapyCartCell TherapyOncologyGene TherapyHealthcare

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 6.7/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.4 / 17
Access Clarity 1.8 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 1.9 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/umoja: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Umoja Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact
Contact

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy

Company 7

The organization behind the API

Website
Website
 About
About
 Blog
Blog
 BlogRSS
BlogRSS
 Careers
Careers
 LinkedIn
LinkedIn
 Twitter
Twitter

Scroll for all 7

Source (apis.yml)

apis.yml Raw ↑ 
aid: umoja
name: Umoja Biopharma
description: Umoja Biopharma is a Seattle-based clinical-stage immuno-oncology company developing in vivo CAR T cell therapies
  for cancer. Its VivoVec lentiviral platform generates CAR T cells directly in a patient's body, removing the ex vivo manufacturing
  step of traditional cell therapy, and the company operates its own manufacturing facility in Louisville, Colorado. Its pipeline
  includes UB-VV111 (CD19), UB-VV400 (the industry's first known CD22-directed in vivo CAR T candidate, FDA IND clearance
  July 2026), and UB-VV500. Umoja is backed by investors including DCVC (DCVC Bio) and SoftBank Vision Fund 2. The company
  publishes no public developer API, OpenAPI, or developer portal; this profile captures the company identity and the security
  posture of its public web surface.
url: https://raw.githubusercontent.com/api-evangelist/umoja/refs/heads/main/apis.yml
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://www.umoja-biopharma.com/wp-content/uploads/2022/08/UMOJA_Facebook.png
x-type: company
x-source: vc-portfolio
x-backed-by:
- dcvc
- softbank-vision-fund
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Biotechnology
- Immunotherapy
- Cart
- Cell Therapy
- Oncology
- Gene Therapy
- Healthcare
tags_raw:
- Company
- Biotechnology
- Immunotherapy
- CAR-T
- Cell Therapy
- Oncology
- Gene Therapy
- Healthcare
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/umoja-domain-security.yml
- type: Website
  url: https://www.umoja-biopharma.com/
- type: About
  url: https://www.umoja-biopharma.com/our-company/
- type: Blog
  url: https://www.umoja-biopharma.com/news/
- type: BlogRSS
  url: https://www.umoja-biopharma.com/feed/
- type: PrivacyPolicy
  url: https://www.umoja-biopharma.com/privacy-policy/
- type: Contact
  url: https://www.umoja-biopharma.com/contact/
- type: Careers
  url: https://www.umoja-biopharma.com/careers/
- type: LinkedIn
  url: https://www.linkedin.com/company/umoja-biopharma/
- type: Twitter
  url: https://twitter.com/UmojaBiopharma
x-enrichment:
  date: '2026-07-21'
  status: minimal
  artifacts_added: 1
  pass: local-v1